[en] Our laboratory has previously identified an important intragenic region in the human immunodeficiency virus type 1 (HIV-1) genome, whose complete functional unit is composed of the 5103 fragment, the DNaseI-hypersensitive site HS7 and the 5105 fragment. These fragments (5103 and 5105) both exhibit a phorbol 12-myristate 13-acetate (PMA)-inducible enhancer activity on the herpes simplex virus thymidine kinase promoter. Here, we characterized the three previously identified AP-1 binding sites of fragment 5103 by showing the PMA-inducible in vitro binding and in vivo recruitment of c-Fos, JunB and JunD to this fragment located at the end of the pol gene. Functional analyses demonstrated that the intragenic AP-1 binding sites are fully responsible for the PMA-dependent enhancer activity of fragment 5103. Moreover, infection of T-lymphoid Jurkat and promonocytic U937 cells with wild-type and mutant viruses demonstrated that mutations of the intragenic AP-1 sites individually or in combination altered HIV-1 replication. Importantly, mutations of the three intragenic AP-1 sites led to a decreased in vivo recruitment of RNA polymerase II to the viral promoter, strongly supporting that the deleterious effect of these mutations on viral replication occurs, at least partly, at the transcriptional level. Single-round infections of monocyte-derived macrophages confirmed the importance of intragenic AP-1 sites for HIV-1 infectivity.
Colin L, Van Lint C, (2009) Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6: 111.
Verdin E, Becker N, Bex F, Droogmans L, Burny A, (1990) Identification and characterization of an enhancer in the coding region of the genome of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 87: 4874-4878.
Verdin E, (1991) DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1. J Virol 65: 6790-6799.
Verdin E, Paras P Jr, Van Lint C, (1993) Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. Embo J 12: 3249-3259.
Van Lint C, Ghysdael J, Paras P Jr, Burny A, Verdin E, (1994) A transcriptional regulatory element is associated with a nuclease-hypersensitive site in the pol gene of human immunodeficiency virus type 1. J Virol 68: 2632-2648.
Goffin V, Demonte D, Vanhulle C, de Walque S, de Launoit Y, et al. (2005) Transcription factor binding sites in the pol gene intragenic regulatory region of HIV-1 are important for virus infectivity. Nucleic Acids Res 33: 4285-4310.
Van Lint C, Burny A, Verdin E, (1991) The intragenic enhancer of human immunodeficiency virus type 1 contains functional AP-1 binding sites. J Virol 65: 7066-7072.
Canonne-Hergaux F, Aunis D, Schaeffer E, (1995) Interactions of the transcription factor AP-1 with the long terminal repeat of different human immunodeficiency virus type 1 strains in Jurkat, glial, and neuronal cells. J Virol 69: 6634-6642.
Van Lint C, Amella CA, Emiliani S, John M, Jie T, et al. (1997) Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. J Virol 71: 6113-6127.
Lee W, Haslinger A, Karin M, Tjian R, (1987) Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40. Nature 325: 368-372.
Hess J, Angel P, Schorpp-Kistner M, (2004) AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117: 5965-5973.
Lee W, Mitchell P, Tjian R, (1987) Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 49: 741-752.
Eferl R, Wagner EF, (2003) AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868.
Vesely PW, Staber PB, Hoefler G, Kenner L, (2009) Translational regulation mechanisms of AP-1 proteins. Mutat Res 682: 7-12.
Boyle WJ, Smeal T, Defize LH, Angel P, Woodgett JR, et al. (1991) Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 64: 573-584.
Davis RJ, (1993) The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 268: 14553-14556.
Bossis G, Malnou CE, Farras R, Andermarcher E, Hipskind R, et al. (2005) Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol Cell Biol 25: 6964-6979.
Garaude J, Farras R, Bossis G, Charni S, Piechaczyk M, et al. (2008) SUMOylation regulates the transcriptional activity of JunB in T lymphocytes. J Immunol 180: 5983-5990.
Ito T, Yamauchi M, Nishina M, Yamamichi N, Mizutani T, et al. (2001) Identification of SWI.SNF complex subunit BAF60a as a determinant of the transactivation potential of Fos/Jun dimers. J Biol Chem 276: 2852-2857.
Yang X, Chen Y, Gabuzda D, (1999) ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappaB. J Biol Chem 274: 27981-27988.
Stein B, Baldwin AS Jr, Ballard DW, Greene WC, Angel P, et al. (1993) Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. Embo J 12: 3879-3891.
Weiss A, Wiskocil RL, Stobo JD, (1984) The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J Immunol 133: 123-128.
Smith SD, Shatsky M, Cohen PS, Warnke R, Link MP, et al. (1984) Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. Cancer Res 44: 5657-5660.
Olive M, Krylov D, Echlin DR, Gardner K, Taparowsky E, et al. (1997) A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J Biol Chem 272: 18586-18594.
Ott M, Emiliani S, Van Lint C, Herbein G, Lovett J, et al. (1997) Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 275: 1481-1485.
Calomme C, Nguyen TL, de Launoit Y, Kiermer V, Droogmans L, et al. (2002) Upstream stimulatory factors binding to an E box motif in the R region of the bovine leukemia virus long terminal repeat stimulates viral gene expression. J Biol Chem 277: 8775-8789.
Osborn L, Kunkel S, Nabel GJ, (1989) Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A 86: 2336-2340.
Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
Flanagin S, Nelson JD, Castner DG, Denisenko O, Bomsztyk K, (2008) Microplate-based chromatin immunoprecipitation method, Matrix ChIP: a platform to study signaling of complex genomic events. Nucleic Acids Res 36: e17.
Nelson JD, Denisenko O, Bomsztyk K, (2006) Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc 1: 179-185.
Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, et al. (2007) Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. Embo J 26: 412-423.
Risse G, Jooss K, Neuberg M, Bruller HJ, Muller R, (1989) Asymmetrical recognition of the palindromic AP1 binding site (TRE) by Fos protein complexes. Embo J 8: 3825-3832.
Krylov D, Kasai K, Echlin DR, Taparowsky EJ, Arnheiter H, et al. (1997) A general method to design dominant negatives to B-HLHZip proteins that abolish DNA binding. Proc Natl Acad Sci U S A 94: 12274-12279.
Marcello A, Zoppe M, Giacca M, (2001) Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator. IUBMB Life 51: 175-181.
Liu YZ, Lania L, Latchman DS, (1996) Functional interaction between the HIV-1 Tat transactivator and the inhibitory domain of the Oct-2 cellular transcription factor. Aids 10: 1323-1329.
Hidalgo-Estevez AM, Gonzalez E, Punzon C, Fresno M, (2006) Human immunodeficiency virus type 1 Tat increases cooperation between AP-1 and NFAT transcription factors in T cells. J Gen Virol 87: 1603-1612.
Chun RF, Semmes OJ, Neuveut C, Jeang KT, (1998) Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat. J Virol 72: 2615-2629.
Demarchi F, d'Adda di Fagagna F, Falaschi A, Giacca M, (1996) Activation of transcription factor NF-kappaB by the Tat protein of human immunodeficiency virus type 1. J Virol 70: 4427-4437.
Malim MH, Hauber J, Fenrick R, Cullen BR, (1988) Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature 335: 181-183.
Chen P, Flory E, Avots A, Jordan BW, Kirchhoff F, et al. (2000) Transactivation of naturally occurring HIV-1 long terminal repeats by the JNK signaling pathway. The most frequent naturally occurring length polymorphism sequence introduces a novel binding site for AP-1 factors. J Biol Chem 275: 20382-20390.
Liebermann DA, Gregory B, Hoffman B, (1998) AP-1 (Fos/Jun) transcription factors in hematopoietic differentiation and apoptosis. Int J Oncol 12: 685-700.
Perez-Bercoff D, David A, Sudry H, Barre-Sinoussi F, Pancino G, (2003) Fcgamma receptor-mediated suppression of human immunodeficiency virus type 1 replication in primary human macrophages. J Virol 77: 4081-4094.
Herschman HR, (1991) Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem 60: 281-319.
Harrich D, Hsu C, Race E, Gaynor RB, (1994) Differential growth kinetics are exhibited by human immunodeficiency virus type 1 TAR mutants. J Virol 68: 5899-5910.
Kim JY, Gonzalez-Scarano F, Zeichner SL, Alwine JC, (1993) Replication of type 1 human immunodeficiency viruses containing linker substitution mutations in the-201 to-130 region of the long terminal repeat. J Virol 67: 1658-1662.
Zeichner SL, Kim JY, Alwine JC, (1991) Analysis of the human immunodeficiency virus long terminal repeat by in vitro transcription competition and linker scanning mutagenesis. Gene Expr 1: 15-27.
Maroder M, Farina AR, Vacca A, Felli MP, Meco D, et al. (1993) Cell-specific bifunctional role of Jun oncogene family members on glucocorticoid receptor-dependent transcription. Mol Endocrinol 7: 570-584.
Li YQ, Hii CS, Der CJ, Ferrante A, (1999) Direct evidence that ERK regulates the production/secretion of interleukin-2 in PHA/PMA-stimulated T lymphocytes. Immunology 96: 524-528.
Marks RE, Ho AW, Rivas F, Marshall E, Janardhan S, et al. (2003) Differential Ras signaling via the antigen receptor and IL-2 receptor in primary T lymphocytes. Biochem Biophys Res Commun 312: 691-696.
Wabnitz GH, Nebl G, Klemke M, Schroder AJ, Samstag Y, (2006) Phosphatidylinositol 3-kinase functions as a Ras effector in the signaling cascade that regulates dephosphorylation of the actin-remodeling protein cofilin after costimulation of untransformed human T lymphocytes. J Immunol 176: 1668-1674.
Wei P, Taniguchi S, Sakai Y, Imamura M, Inoguchi T, et al. (2005) Expression of adipose differentiation-related protein (ADRP) is conjointly regulated by PU.1 and AP-1 in macrophages. J Biochem 138: 399-412.
Behre G, Whitmarsh AJ, Coghlan MP, Hoang T, Carpenter CL, et al. (1999) c-Jun is a JNK-independent coactivator of the PU.1 transcription factor. J Biol Chem 274: 4939-4946.
Ueda K, Wei Y, Ganem D, (1996) Activation of N-myc2 gene expression by cis-acting elements of oncogenic hepadnaviral genomes: key role of enhancer II. Virology 217: 413-417.
Moolla N, Kew M, Arbuthnot P, (2002) Regulatory elements of hepatitis B virus transcription. J Viral Hepat 9: 323-331.
Inoshima Y, Kohmoto M, Ikeda Y, Yamada H, Kawaguchi Y, et al. (1996) Roles of the auxiliary genes and AP-1 binding site in the long terminal repeat of feline immunodeficiency virus in the early stage of infection in cats. J Virol 70: 8518-8526.
Maurer B, Serfling E, ter Meulen V, Rethwilm A, (1991) Transcription factor AP-1 modulates the activity of the human foamy virus long terminal repeat. J Virol 65: 6353-6357.
Meiering CD, Rubio C, May C, Linial ML, (2001) Cell-type-specific regulation of the two foamy virus promoters. J Virol 75: 6547-6557.
Cohen A, Brodie C, Sarid R, (2006) An essential role of ERK signalling in TPA-induced reactivation of Kaposi's sarcoma-associated herpesvirus. J Gen Virol 87: 795-802.
Xie J, Ajibade AO, Ye F, Kuhne K, Gao SJ, (2008) Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology 371: 139-154.
Thierry F, Spyrou G, Yaniv M, Howley P, (1992) Two AP1 sites binding JunB are essential for human papillomavirus type 18 transcription in keratinocytes. J Virol 66: 3740-3748.
Prusty BK, Das BC, (2005) Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int J Cancer 113: 951-960.
Morse BA, Carruth LM, Clements JE, (1999) Targeting of the visna virus tat protein to AP-1 sites: interactions with the bZIP domains of fos and jun in vitro and in vivo. J Virol 73: 37-45.
Basbous J, Arpin C, Gaudray G, Piechaczyk M, Devaux C, et al. (2003) The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. J Biol Chem 278: 43620-43627.
Peloponese JM Jr, Jeang KT, (2006) Role for Akt/protein kinase B and activator protein-1 in cellular proliferation induced by the human T-cell leukemia virus type 1 tax oncoprotein. J Biol Chem 281: 8927-8938.